We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

41 hedge funds and large institutions have $23.7M invested in vTv Therapeutics in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 17 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

31% more capital invested

Capital invested by funds: $18M → $23.7M (+$5.67M)

0.03% less ownership

Funds ownership: 0.96% → 0.93% (-0.03%)

7% less funds holding

Funds holding: 44 → 41 (-3)

41% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 17

Holders
41
Holders Change
-3
Holders Change %
-6.82%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
10
Reduced
17
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.39M
2
CS
Candriam SCA
Luxembourg
+$798K
3
SFM
Sphera Funds Management
Israel
+$570K
4
EIM
Essex Investment Management
Massachusetts
+$227K
5
GCP
GSA Capital Partners
United Kingdom
+$188K

Top Sellers

Rank Fund Capital Flow
1
GTC
Ghost Tree Capital
New York
-$966K
2
Stifel Financial
Stifel Financial
Missouri
-$157K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$59K
4
SM
Sabby Management
Florida
-$49.9K
5
Morgan Stanley
Morgan Stanley
New York
-$36.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIG
26
American International Group
New York
$31K +$1.82K +8 +7%
New York State Common Retirement Fund
27
New York State Common Retirement Fund
New York
$28K – – –
Manulife (Manufacturers Life Insurance)
28
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$9K – – –
Bank of America
29
Bank of America
North Carolina
$9K +$1.82K +8 +31%
TRCT
30
Tower Research Capital (TRC)
New York
$7K -$6.39K -28 -53%
FPF
31
FNY Partners Fund
New York
$7K +$7.07K +31 New
Legal & General Group
32
Legal & General Group
United Kingdom
$6K -$7.07K -31 -58%
MAM
33
Meeder Asset Management
Ohio
$5K -$4.79K -21 -51%
Wells Fargo
34
Wells Fargo
California
$5K +$4.56K +20 New
AG
35
Advisor Group
Arizona
$3K +$2.28K +10 New
AIP
36
Ameritas Investment Partners
Nebraska
$3K +$2.96K +13 New
UBS Group
37
UBS Group
Switzerland
$2K -$5.47K -24 -80%
BNP Paribas Financial Markets
38
BNP Paribas Financial Markets
France
$1.03K -$2.05K -9 -69%
Citigroup
39
Citigroup
New York
$1K -$8.89K -39 -91%
Barclays
40
Barclays
United Kingdom
$1K -$1.82K -8 -67%
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$1K -$1.14K -5 -45%
GTC
42
Ghost Tree Capital
New York
– -$966K -5,000 Closed
Stifel Financial
43
Stifel Financial
Missouri
– -$157K -818 Closed
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
– -$59K -307 Closed
Creative Planning
45
Creative Planning
Kansas
– -$5K -25 Closed
SEI Investments
46
SEI Investments
Pennsylvania
– -$1K -3 Closed
1
2

VTVT Hedge Fund Activity: Q1 2017 in Review

41 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q1 2017, worth a combined $23.7M — up 31% from $18M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new VTVT positions and 5 closed out — a net gain of 3 holders — while 10 added to existing stakes and 17 trimmed.

The largest buyer was BlackRock, adding an estimated $2.39M. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $966K sold.

  • 41 institutional investors held vTv Therapeutics (VTVT) as of Q1 2017, down from 44 in Q4 2016.
  • Funds reported $23.7M of vTv Therapeutics stock for Q1 2017, up 31% quarter-over-quarter.
  • 8 funds opened new vTv Therapeutics positions in Q1 2017 and 5 closed out, a net change of +3 holders.
  • The largest vTv Therapeutics buyer in Q1 2017 was BlackRock, an estimated $2.39M added.
  • The largest vTv Therapeutics seller in Q1 2017 was Ghost Tree Capital, an estimated $966K sold.

Based on aggregated 13F filings for Q1 2017.